ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
- RxCUI
- 2612675
- RxNorm name
- ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
- Display name
- ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
- Full name
- ranibizumab-eqrn 0.3 MG in 0.05 ML Injection
- Term type
- PSN
- Status
- DailyMed mapping
- Updated
- 2026-06-04 23:39:24
Purple Book Biologic Products#
| BLA | Proprietary name | Proper name | License type | Status | Latest source |
|---|---|---|---|---|---|
| 761165 | Cimerli | ranibizumab-eqrn | 351(k) Interchangeable | Rx | 2026-06-01 |
UNII Substances#
No records found.
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| CIMERLI | RANIBIZUMAB-EQRN | Coherus BioSciences Inc | e0e23118-1490-a554-e053-2995a90ab90c | 2025-05-07 | Warnings, Adverse reactions | 2612675 |
| CIMERLI | RANIBIZUMAB-EQRN | Sandoz Inc | 4b383d74-4830-4587-95f7-c32a39268df7 | 2024-06-17 | Warnings, Adverse reactions | 2612675 |
DailyMed RxNorm Mappings#
| Set ID | RxNorm string | TTY | SPL version | Label | Effective |
|---|---|---|---|---|---|
| e0e23118-1490-a554-e053-2995a90ab90c | ranibizumab-eqrn 0.3 MG per 0.05 ML Injection | SY | 12 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | 20250507 |
| e0e23118-1490-a554-e053-2995a90ab90c | ranibizumab-eqrn 6 MG/ML per 0.05 ML Injection | SY | 12 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | 20250507 |
| e0e23118-1490-a554-e053-2995a90ab90c | 0.05 ML ranibizumab-eqrn 6 MG/ML Injection | SCD | 12 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | 20250507 |
| e0e23118-1490-a554-e053-2995a90ab90c | ranibizumab-eqrn 0.3 MG in 0.05 ML Injection | PSN | 12 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI™ (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences bet | 20250507 |
| 4b383d74-4830-4587-95f7-c32a39268df7 | ranibizumab-eqrn 0.3 MG in 0.05 ML Injection | PSN | 3 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | 20240617 |
| 4b383d74-4830-4587-95f7-c32a39268df7 | ranibizumab-eqrn 6 MG/ML per 0.05 ML Injection | SY | 3 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | 20240617 |
| 4b383d74-4830-4587-95f7-c32a39268df7 | 0.05 ML ranibizumab-eqrn 6 MG/ML Injection | SCD | 3 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | 20240617 |
| 4b383d74-4830-4587-95f7-c32a39268df7 | ranibizumab-eqrn 0.3 MG per 0.05 ML Injection | SY | 3 | These highlights do not include all the information needed to use CIMERLI safely and effectively. See full prescribing information for CIMERLI. CIMERLI ® (ranibizumab-eqrn) injection, for intravitreal use Initial U.S. Approval: 2022 CIMERLI (ranibizumab-eqrn) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences be | 20240617 |